2 citations
,
January 2011 in “Clinical medicine insights” The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.
May 2024 in “KIU journal of health science” In this study, kolaviron and quercetin were found to reverse elevated biomarkers associated with testosterone-induced benign prostatic hyperplasia in Wistar rats, with both treatments effectively increasing HDL-c levels, though quercetin did not significantly affect triglyceride levels.
11 citations
,
March 2014 in “Journal of The European Academy of Dermatology and Venereology” In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.
January 2018 in “Elsevier eBooks” This review discusses the role of DHT in male sexual differentiation and fertility in individuals with 5α-reductase-2 deficiency, reporting no new clinical results.
3 citations
,
February 2013 in “PubMed” This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.